Rabbit Recombinant Monoclonal TAU phospho T217 antibody. Suitable for Dot, sELISA, I-ELISA and reacts with Synthetic peptide - Human, Human, Recombinant full length protein - Human samples. Cited in 1 publication.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
IHC-P | Dot | sELISA | I-ELISA | |
---|---|---|---|---|
Human | Not recommended | Expected | Tested | Expected |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended |
Recombinant full length protein - Human | Not recommended | Not recommended | Tested | Not recommended |
Synthetic peptide - Human | Not recommended | Tested | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Synthetic peptide - Human, Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Recombinant full length protein - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant full length protein - Human | Dilution info - | Notes Use at 31.25 ng/ml. |
Species Human | Dilution info - | Notes Use at 31.25 ng/ml. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Synthetic peptide - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Synthetic peptide - Human | Dilution info - | Notes Use at 31.25 ng/ml. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Recombinant full length protein - Human | Dilution info - | Notes - |
Select an associated product type
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
MAPT phospho T217, MAPT phospho T217
MAPTL, MTBT1, TAU, MAPT, Microtubule-associated protein tau, Neurofibrillary tangle protein, Paired helical filament-tau, PHF-tau
Rabbit Recombinant Monoclonal TAU phospho T217 antibody. Suitable for Dot, sELISA, I-ELISA and reacts with Synthetic peptide - Human, Human, Recombinant full length protein - Human samples. Cited in 1 publication.
IgG
Rabbit
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR24654-24
Affinity purification Protein A
The specificity of this antibody refers to P10636-8.
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
Tau also known as microtubule-associated protein Tau (MAPT) plays an important role in stabilizing microtubules in neuronal cells. Tau is primarily found in the central nervous system but also exists in peripheral neurons. Human Tau protein comes in six isoforms due to alternative splicing with molecular weights ranging from 48 kDa to 67 kDa. This protein predominantly locates in the axons of neurons where it maintains the stability of microtubule tracks necessary for axonal transport.
Tau is involved in the assembly and stabilization of microtubules essential for maintaining neuronal structure. It interacts with microtubule-binding domains (MBD) to bind and bundle microtubules facilitating intracellular transport. Tau forms a part of the neuronal cytoskeleton complex working closely with other cytoskeletal proteins to preserve the proper axonal transport and function. Abnormally phosphorylated Tau often termed phospho-Tau disrupts this complex affecting microtubule stability.
Tau has critical involvement in several signaling cascades such as the microtubule-binding and transport pathways. Glycogen synthase kinase 3 beta (GSK3β) and cyclin-dependent kinase 5 (CDK5) frequently phosphorylate Tau controlling its interaction with microtubules. Phosphorylated Tau accumulates leading to the formation of neurofibrillary tangles often observed in neurodegenerative conditions. Additionally Tau interacts with GAPDH impacting cellular energy regulation through potential pathway cross-talk involving oxidative stress responses.
Tau is closely associated with Alzheimer's disease and frontotemporal dementia. In Alzheimer's disease hyperphosphorylated Tau aggregates into paired helical filaments forming neurofibrillary tangles while similar aggregates are observed in frontotemporal dementia. In these conditions Tau links to amyloid precursor protein (APP) where misregulated phosphorylation-driven interactions contribute to neurodegeneration. Identifying phospho-Tau and its altered interactions with related proteins aids in understanding and potentially treating these disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Indirect ELISA antibody dose-response curve using Human Tau non-phospho and Human Tau phospho T217 antigens. Antigen concentration was 1000 ng/mL. ab288160 was added at 0 - 1000 ng/mL. Samples were incubated with Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) secondary antibody at 1/2500 dilution.
Dot blot analysis using ab288160 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) ab97051 (Peroxidase conjugated goat anti-rabbit IgG (H+L)) secondary antibody at 1/100000 dilution.
Lane 1: Tau (phospho T217) peptide
Lene 2: Tau (phospho T220) peptide
Lane 3: Tau non-phosphoppotide
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
This image data was created using the same antibody clone in a different buffer formulation (ab288167).
Standard Curve for human pTau (Analyte: human recombinant pTau protein at a concentration 0.5-1,000 pg/ml); using Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free (Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free ab288167) in a ligand binding assay at 125 ng/well paired with a total Tau antibody. The data was obtained on the Singulex platform.
The data was kindly provided by a collaborator.
This image data was created using the same antibody clone in a different buffer formulation (ab288167).
Recovery for fluidic matrices (human CSF and plasma) at indicated dilutions using Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free (Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free ab288167) in a ligand binding assay at 125 ng/well paired with a total Tau antibody. The data was obtained on the Singulex platform.
The data was kindly provided by a collaborator.
This image data was created using the same antibody clone in a different buffer formulation (ab288167).
The concentration of pTau217 in human soluble brain extracts from Alzheimer's disease patients (AD) and healthy controls (Ctrl) (n = 6) was quantified using the Singulex platform. Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free (Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free ab288167) was used in a ligand binding assay at 125 ng/well paired with a total Tau antibody. The effect size AD vs. Ctrl. is 3.2 for soluble brain extracts.
The data was kindly provided by a collaborator.
This image data was created using the same antibody clone in a different buffer formulation (ab288167).
The concentration of human pTau217 in human plasma samples from Alzheimer's disease patients (AD) and healthy controls (Ctrl) (n = 11) was quantified using the Singulex platform. Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free (Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free ab288167) was used in a ligand binding assay at 125 ng/well paired with a total Tau antibody. The effect size AD vs. Ctrl. is 4.5 for plasma samples.
The data was kindly provided by a collaborator.
This image data was created using the same antibody clone in a different buffer formulation (ab288167).
The concentration of pTau217 in matched human cerebrospinal fluid (CSF) and plasma samples from Alzheimer's disease patients (AD) and healthy controls (Ctrl) (n = 6) was quantified using the Singulex platform. Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free (Anti-Tau (phospho T217) antibody [EPR24654-24] - BSA and Azide free ab288167) was used in a ligand binding assay at 125 ng/well paired with a total Tau antibody. The effect size AD vs. Ctrl. is 14.7 for CSF samples.
The data was kindly provided by a collaborator.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com